1
00:00:02,000 --> 00:00:08,200
Eloralintide is a once-weekly amylin analog developed by Eli Lilly.

2
00:00:09,060 --> 00:00:11,280
Its design asks a focused question.

3
00:00:11,820 --> 00:00:15,660
Can receptor selectivity improve the treatment of obesity?

4
00:00:16,540 --> 00:00:21,000
Daniel Briere and colleagues described its discovery in 2025.

5
00:00:22,040 --> 00:00:25,500
Human receptor assays found 12 times greater potency

6
00:00:25,500 --> 00:00:29,460
at the amylin-one receptor than at the calcitonin receptor.

7
00:00:30,280 --> 00:00:31,660
That is a laboratory measurement.

8
00:00:31,660 --> 00:00:34,160
It does not mean 12 times more weight

9
00:00:34,160 --> 00:00:37,220
loss or prove better tolerability in patients.

10
00:00:38,000 --> 00:00:42,640
Liana Billings and colleagues studied 263 adults for

11
00:00:42,640 --> 00:00:46,480
48 weeks in a randomized phase 2 trial.

12
00:00:47,200 --> 00:00:50,360
Participants had obesity or overweight with a related

13
00:00:50,360 --> 00:00:53,180
condition without type 2 diabetes.

14
00:00:54,120 --> 00:00:58,260
Estimated average weight reductions ranged from 9.5 to

15
00:00:58,260 --> 00:01:05,260
20.1% across six active groups versus 0.4% with placebo.

16
00:01:06,140 --> 00:01:09,480
These estimates assume participants remained on treatment.

17
00:01:09,950 --> 00:01:14,873
Weight loss is only part of the picture. Tolerability matters too.

18
00:01:15,343 --> 00:01:18,163
Gastrointestinal symptoms and fatigue were common.

19
00:01:18,743 --> 00:01:22,463
Slower dose escalation was associated with fewer of these events.

20
00:01:23,183 --> 00:01:27,123
Long-term safety and sustained benefit remain research questions.

21
00:01:27,903 --> 00:01:29,183
As of October 14,

22
00:01:29,963 --> 00:01:36,223
2026, Eloralintide remains investigational with phase 3 studies underway.

23
00:01:36,223 --> 00:01:40,523
Tirzepatide combination results are separate evidence.

24
00:01:41,263 --> 00:01:43,183
Next, survodutide.

25
00:01:43,403 --> 00:01:46,375
The next chapter depends on longer-term evidence.

26
00:01:46,595 --> 00:01:48,075
Peptides in 2.

27
00:01:48,075 --> 00:01:49,895
World Peptide Foundation.

28
00:01:50,615 --> 00:01:51,895
Every experience matters.